Compare Summit Therapeutics Inc (SMMT) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Summit Therapeutics Inc trades at $17.45 (market cap $13.71B), while YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M). The key difference: Summit Therapeutics Inc is far larger — about 37.7× YieldMax Universe Fund of Option Income ETFs's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| SMMT | YMAX | |
|---|---|---|
Market Cap | $13.71B | $364M |
Volume | 6,173,057 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.38 | $12.98 |
52-Week Low | $12.43 | $7.27 |
Typical Hold Time | 16 Days | 56 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
YMAX trades at $7.53, down 1.83% on the day, with a bearish technical signal from moving averages. The ETF maintains weekly dividend distributions but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues, though the fund's structure as a fund-of-funds adds additional cost layers that impact returns.
The outlook remains cautious due to structural concerns and persistent share price decline despite high yield. Investment opportunity exists for income-focused investors willing to accept principal erosion risks, while the primary risk involves unsustainable distribution policy and compounding fees affecting long-term total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
